A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2015
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 24 Mar 2015 Results presented at the 73rd Annual Meeting of the American Academy of Dermatology.
- 25 Feb 2014 As per the ClinicalTrials.gov record, status changed from recruiting to completed.
- 16 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.